Viewing Study NCT06647732

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 9:55 PM
Ignite Modification Date: 2026-01-01 @ 11:24 PM
Study NCT ID: NCT06647732
Status: RECRUITING
Last Update Posted: 2025-03-13
First Post: 2024-10-16
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Zanubrutinib Plus Rituximab As Front-line Treatment for Mucosa-associated Lymphoid Tissue Lymphoma (MALT)
Sponsor: Sun Yat-sen University
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Mucosa-associated Lymphoid Tissue Lymphoma (MALT) View
Keywords: